USANA Health Sciences (NASDAQ:USNA) issued its quarterly earnings data on Wednesday. The company reported $1.16 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.14 by $0.02, Analyst Ratings News reports. The company had revenue of $173.70 million for the quarter, compared to the consensus estimate of $172.40 million. During the same quarter in the prior year, the company posted $1.18 earnings per share. The company’s quarterly revenue was up 5.1% on a year-over-year basis.
In other USANA Health Sciences news, major shareholder Holdings Ltd Gull sold 7,000 shares of USANA Health Sciences stock on the open market in a transaction dated Wednesday, October 9th. The stock was sold at an average price of $80.08, for a total value of $560,560.00. Following the sale, the insider now directly owns 6,581,167 shares in the company, valued at approximately $527,019,853. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
On the ratings front, analysts at Janney Montgomery Scott raised their price target on shares of USANA Health Sciences from $49.00 to $72.00 in a research note to investors on Thursday, July 25th. They now have a “neutral” rating on the stock. Four investment analysts have rated the stock with a hold rating, The company has an average rating of “Hold” and a consensus price target of $74.28.
USANA Health Sciences (NASDAQ:USNA) opened at 91.41 on Wednesday. USANA Health Sciences has a 52 week low of $30.51 and a 52 week high of $87.40. The stock has a 50-day moving average of $79.6 and a 200-day moving average of $65.25. The company has a market cap of $1.260 billion and a price-to-earnings ratio of 16.08.
USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.